247 related articles for article (PubMed ID: 32692628)
1. Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.
Sathyanarayanan V; Flowers CR; Iyer SP
JCO Glob Oncol; 2020 Jul; 6():1124-1133. PubMed ID: 32692628
[TBL] [Abstract][Full Text] [Related]
2. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
[TBL] [Abstract][Full Text] [Related]
3. Rituximab biosimilars for lymphoma in Europe.
Jurczak W; Długosz Danecka M; Buske C
Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
[No Abstract] [Full Text] [Related]
4. Economic perspective of cancer treatment in India.
Natarajan A; Mehra N; Rajkumar T
Med Oncol; 2020 Oct; 37(11):101. PubMed ID: 33057841
[TBL] [Abstract][Full Text] [Related]
5. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing Safety of Biosimilars: Current Status, Challenges, and Opportunities in the Spontaneous Reporting System.
Singh A; Kalaivani M; Srivastava S; Goyal RK; Gupta SK
Ther Innov Regul Sci; 2020 May; 54(3):667-680. PubMed ID: 33301154
[TBL] [Abstract][Full Text] [Related]
7. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
[TBL] [Abstract][Full Text] [Related]
8. Use of Biologics and Biosimilars in Rheumatology.
Sharma SK
J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars: are they ready for primetime in the United States?
Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2011 Aug; 9(8):934-42; quiz 943. PubMed ID: 21900222
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
11. The role of generic medicines and biosimilars in oncology in low-income countries.
Renner L; Nkansah FA; Dodoo AN
Ann Oncol; 2013 Sep; 24 Suppl 5():v29-32. PubMed ID: 23975702
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
13. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
Buske C; Ogura M; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in psoriasis: the future or not?
Kellen R; Goldenberg G
Cutis; 2017 Feb; 99(2):116-120. PubMed ID: 28319617
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: the need, the challenge, the future: the FDA perspective.
Epstein MS; Ehrenpreis ED; Kulkarni PM;
Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
[TBL] [Abstract][Full Text] [Related]
16. Regulatory and clinical considerations for biosimilar oncology drugs.
Bennett CL; Chen B; Hermanson T; Wyatt MD; Schulz RM; Georgantopoulos P; Kessler S; Raisch DW; Qureshi ZP; Lu ZK; Love BL; Noxon V; Bobolts L; Armitage M; Bian J; Ray P; Ablin RJ; Hrushesky WJ; Macdougall IC; Sartor O; Armitage JO
Lancet Oncol; 2014 Dec; 15(13):e594-e605. PubMed ID: 25456378
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.
Feldman SR; Bagel J; Namak S
Am J Med Sci; 2018 May; 355(5):411-417. PubMed ID: 29753369
[TBL] [Abstract][Full Text] [Related]
18. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies.
Castañeda-Hernández G; Szekanecz Z; Mysler E; Azevedo VF; Guzman R; Gutierrez M; Rodríguez W; Karateev D
Joint Bone Spine; 2014 Dec; 81(6):471-7. PubMed ID: 24956990
[TBL] [Abstract][Full Text] [Related]
19. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
Chen Q; Jain N; Ayer T; Wierda WG; Flowers CR; O'Brien SM; Keating MJ; Kantarjian HM; Chhatwal J
J Clin Oncol; 2017 Jan; 35(2):166-174. PubMed ID: 27870563
[TBL] [Abstract][Full Text] [Related]
20. Biologic Drugs, Biosimilars, and Barriers to Entry.
Shepherd JM
Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
